Huxley Pharmaceuticals Inc. acquired by BioMarin Pharmaceutical Inc.
|
|
|
|
|
proprietary form of 3.4-diaminopyridine (3.4-DAP); amifampridine phosphate; for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS) | |
Korean Distributor : ??? |
Products information :
|
|
|
|
|
|
|
|
|
|